Endocyte

What Endocyte does

Endocyte was a US biopharmaceutical company founded in 1996 by Philip Low at Purdue University to develop receptor-targeted therapeutics, with a primary focus on cancer and inflammatory diseases. Its core technology was a radioligand therapy (RLT) platform that delivered cytotoxic radiation to cancer cells using ligand-linker-radionuclide complexes, anchored on proprietary PSMA-targeting chemistry and complemented by companion diagnostic imaging agents for patient selection. The platform produced three distinct FDA-approved oncology products — Pluvicto (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer, and the imaging/diagnostic agents Cytalux and Locametz — with clinical trials reporting cancer clearance rates rising from 9% to 21%.

The company's business model was R&D-driven biotech value creation, not standalone commercial sales: it monetized its platform through a strategic exit, being acquired by Novartis for $2.1 billion in 2018. Following the acquisition, Endocyte became a wholly-owned subsidiary of Novartis and ceased independent operations; the products and pipeline it originated are now sold through Novartis's global specialty pharmaceutical distribution and nuclear medicine channel. Pre-acquisition, Endocyte funded development through approximately $113 million in disclosed venture equity and debt rounds (2001–2010) led by Sanderling Ventures and other life-science investors, with Blue Chip Venture Company, Burrill & Company, and CID Equity Partners as repeat backers. Customer-facing distribution to oncology hospitals, cancer treatment centers, and nuclear medicine facilities — requiring handling of radiopharmaceuticals with a 3-5 day delivery window — is now executed inside Novartis.

Name

Endocyte

Legal name

Endocyte Inc.

Website

https://endocyte.com

Company type

Private

Founded year

1996

Operating status

Acquired

Headcount range

51–100 employees

Short description

Endocyte was a US biotech founded in 1996 that developed receptor-targeted radioligand therapies for cancer, pioneering PSMA-targeted therapeutics that became Pluvicto, Cytalux, and Locametz before its $2.1 billion acquisition by Novartis in 2018.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Oncology Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

Keywords

• Radioligand therapy
• Targeted cancer therapeutics
• Prostate cancer treatment
• PSMA-targeted therapy
• Radiopharmaceutical development

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product development and commercialization: Endocyte developed novel cancer therapies through proprietary research and development. The company was acquired by Novartis for $2.1 billion in 2018, representing the primary exit and revenue realization for investors.

Distribution channels1 record

Marketing channels1 record

Core offering

Endocyte developed receptor-targeted therapeutics for cancer using a proprietary radioligand therapy platform that delivers cytotoxic radiation via ligand-linker-radionuclide complexes. Its lead technology targeted PSMA (prostate-specific membrane antigen) and produced the FDA-approved radioligand therapy Pluvicto (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer, along with companion imaging agents Locametz and Cytalux. Endocyte was acquired by Novartis for $2.1 billion in 2018 and now operates as a wholly-owned subsidiary whose products are commercialized within Novartis's oncology portfolio.

Product overview

Endocyte was a US biotech company focused on developing targeted cancer therapies using small molecule drug conjugates and radiopharmaceutical technology. The company's proprietary platform led to multiple cancer therapeutics. Endocyte was acquired by Novartis for $2.1 billion in 2018, and its technology portfolio produced three marketed cancer drugs: Pluvicto (radioligand therapy for prostate cancer), Cytalux, and Locametz. As a result of the acquisition, Endocyte's products and pipeline are now incorporated into Novartis's oncology portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Pluvicto (177Lu-PSMA-617) Radioligand therapy using [177Lu]Lu-PSMA-617 to deliver cytotoxic radiation directly to PSMA-positive metastatic castration-resistant prostate cancer cells via a ligand-linker-radionuclide complex; for hospitals, cancer treatment centers, and nuclear medicine facilities treating mCRPC patients.
• Cytalux Cancer diagnostic/therapeutic agent derived from Endocyte's targeted cancer therapy intellectual property, commercialized by Novartis following the 2018 acquisition.
• Locametz FDA-approved companion diagnostic imaging agent used to identify PSMA-positive patients eligible for Pluvicto radioligand therapy; supports theranostic patient stratification for oncology providers.

Quantifiable outcome

• Pluvicto achieved $1.04 billion sales in first three quarters of 2024
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• NovartisflagshipStrategic or Co-development Partner · 1 January 2018Novartis acquired Endocyte for $2.1 billion in 2018, bringing the company's PSMA-targeted radioligand therapy technology into Novartis's oncology portfolio. The acquisition led to Pluvicto, which generated nearly $2 billion in sales in 2025 and is central to Novartis's goal of reaching $5 billion in peak sales.

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• Novartis: Acquired Endocyte for $2.1B in 2018 and now owns and commercializes Pluvicto, Cytalux, and Locametz. The largest investor in radiopharmaceuticals with ~$6B in sector M&A including Advanced Accelerator Applications (LUTATHERA), giving it a comprehensive radioligand franchise built substantially on Endocyte's IP.
• AstraZeneca: Has invested in radioconjugate platforms (including Fusion Pharmaceuticals acquisition for alpha-emitter therapies) and is building a competing pipeline to Novartis's radioligand franchise.
• Bayer: Markets Xofigo (radium-223) for metastatic prostate cancer and is investing heavily in radioligand therapies including PSMA-targeted programs. A large pharmaceutical incumbent with overlapping prostate-cancer radiopharmaceutical interests.
• Curium: World's largest manufacturer of radiopharmaceuticals and a major supplier of PET isotopes and SPECT agents. Provides manufacturing infrastructure relevant to Endocyte's technology and competes broadly in nuclear medicine.
• Eli Lilly: Acquired Point Biopharma in 2023 to enter the radioligand therapy space, directly mirroring Novartis's Endocyte acquisition strategy. A large pharma incumbent now pursuing the same PSMA opportunity.

Direct peers

• ITM Isotope Technologies Munich: Develops targeted radionuclide therapies and diagnostic radiopharmaceuticals, including proprietary Lu-177-based and novel radionuclide platforms directly comparable to Endocyte's ligand-linker-radionuclide approach.
• Telix Pharmaceuticals: Directly competes with Endocyte-derived Pluvicto in the PSMA radioligand space, with Illuccix (68Ga-PSMA-11) as a companion diagnostic and an investigational TLX591 (177Lu-rosopatamab) therapeutic. Most head-to-head commercial peer in PSMA-targeted prostate cancer imaging and therapy.
• Lantheus Holdings: Specialty radiopharmaceutical company with PSMA imaging agent Pylarify (18F-DCFPyL) and an expanding radioligand therapy pipeline. Competes with Endocyte's PSMA platform on the diagnostic side and increasingly on the therapeutic side.
• Point Biopharma: Developed PSMA-targeted radioligand therapy PNT2002 and actinium-225-based pipeline. Direct technology peer that was acquired by Eli Lilly in 2023, validating the strategic value of radioligand platforms similar to Endocyte's.

Emerging players

• Philogen: Develops targeted ligand-based therapeutics (cytokines and antibody fragments) including radio-conjugates for cancer. Comparable in that it applies targeted-ligand delivery — similar conceptual framework to Endocyte's receptor-targeted approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/novartis
• Facebookfacebook.com/novartis
• LinkedInlinkedin.com/company/independent-consultant-for-endocyte

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endocyte